Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.

[1]  T. Oron,et al.  Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2 , 2019, Diabetes Care.

[2]  N. Shaat,et al.  Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies , 2019, Diabetologia.

[3]  H. Murphy,et al.  Suboptimal Nocturnal Glucose Control Is Associated With Large for Gestational Age in Treated Gestational Diabetes Mellitus , 2019, Diabetes Care.

[4]  David M Maahs,et al.  State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. , 2019, Diabetes technology & therapeutics.

[5]  Chantal M. Mcmahon,et al.  The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. , 2019, Diabetes technology & therapeutics.

[6]  David Rodbard,et al.  The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c , 2019, Journal of diabetes science and technology.

[7]  Roy W Beck,et al.  The Association of Biochemical Hypoglycemia with the Subsequent Risk of a Severe Hypoglycemic Event: Analysis of the DCCT Data Set. , 2019, Diabetes technology & therapeutics.

[8]  Tadej Battelino,et al.  Continuous glucose monitoring use and glucose variability in pre-school children with type 1 diabetes. , 2019, Diabetes research and clinical practice.

[9]  D. Hinnen,et al.  Reference Guide for Integrating Continuous Glucose Monitoring Into Clinical Practice , 2018, The Diabetes educator.

[10]  Eric P. Smith,et al.  When HbA1c and Blood Glucose Do Not Match: How Much Is Determined by Race, by Genetics, by Differences in Mean Red Blood Cell Age? , 2018, The Journal of clinical endocrinology and metabolism.

[11]  Dennis R Harris,et al.  Approach to Using Trend Arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in Adults , 2018, Journal of the Endocrine Society.

[12]  R. Beck,et al.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials , 2018, Diabetes Care.

[13]  M. Phillip,et al.  Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study , 2018, Diabetes Care.

[14]  D. Maahs,et al.  ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes , 2018, Pediatric diabetes.

[15]  Korey K Hood,et al.  ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies , 2018, Pediatric diabetes.

[16]  R. Beck,et al.  Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring , 2018, Diabetes Care.

[17]  Y. Bao,et al.  Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes , 2018, Diabetes Care.

[18]  L. Lim,et al.  Continuous glucose monitoring results in lower HbA1c in Malaysian women with insulin‐treated gestational diabetes: a randomized controlled trial , 2018, Diabetic medicine : a journal of the British Diabetic Association.

[19]  R. Beck,et al.  Marked Increases in CGM Use Has Not Prevented Increases in HbA1c Levels in Participants in the T1D Exchange (T1DX) Clinic Network , 2018, Diabetes.

[20]  RodbardDavid.  Glucose Variability: A Review of Clinical Applications and Research Developments , 2018 .

[21]  D. Rodbard.  Glucose Variability: A Review of Clinical Applications and Research Developments. , 2018, Diabetes technology & therapeutics.

[22]  L. Lim,et al.  Beyond HbA1c: Comparing Glycemic Variability and Glycemic Indices in Predicting Hypoglycemia in Type 1 and Type 2 Diabetes. , 2018, Diabetes technology & therapeutics.

[23]  R. Bergenstal,et al.  Time Savings Using a Standardized Glucose Reporting System and Ambulatory Glucose Profile , 2018, Journal of diabetes science and technology.

[24]  Stefania Guerra,et al.  Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial , 2018, The Lancet.

[25]  Roy W Beck,et al.  Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control. , 2018, Diabetes technology & therapeutics.

[26]  R. Hovorka,et al.  Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial , 2018, Diabetes Care.

[27]  N. Oliver,et al.  A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia , 2017, Diabetic medicine : a journal of the British Diabetic Association.

[28]  Michelle Perkins,et al.  Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial , 2017, The Lancet.

[29]  Gregory P. Forlenza,et al.  A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With Diabetes , 2017, Journal of the Endocrine Society.

[30]  Ruth S. Weinstock,et al.  A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System for the Management of Adults With Diabetes , 2017, Journal of the Endocrine Society.

[31]  Eyal Dassau,et al.  International Consensus on Use of Continuous Glucose Monitoring , 2017, Diabetes Care.

[32]  G. A. Fleming,et al.  Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations , 2017, Diabetes Care.

[33]  G. A. Fleming,et al.  Improving the clinical value and utility of CGM systems: issues and recommendations , 2017, Diabetologia.

[34]  J. McGill,et al.  Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. , 2017, Annals of internal medicine.

[35]  I. Hirsch,et al.  PROFESSIONAL FLASH CONTINUOUS GLUCOSE MONITORING WITH AMBULATORY GLUCOSE PROFILE REPORTING TO SUPPLEMENT A1C: RATIONALE AND PRACTICAL IMPLEMENTATION. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[36]  Roy W Beck,et al.  The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading , 2017, Diabetes Care.

[37]  R. Bergenstal,et al.  Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes , 2017, Diabetes technology & therapeutics.

[38]  L. Pedersen,et al.  Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiators , 2017, Diabetes Care.

[39]  Danielle Hessler,et al.  The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial , 2017, Diabetes Care.

[40]  Tadej Battelino,et al.  Prevention of Hypoglycemia With Predictive Low Glucose Insulin Suspension in Children With Type 1 Diabetes: A Randomized Controlled Trial , 2017, Diabetes Care.

[41]  Alan Bernjak,et al.  Diurnal Differences in Risk of Cardiac Arrhythmias During Spontaneous Hypoglycemia in Young People With Type 1 Diabetes , 2017, Diabetes Care.

[42]  Rodica Pop-Busui,et al.  REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Well-Controlled Adults With Type 1 Diabetes , 2017 .

[43]  Howard Wolpert,et al.  Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial , 2017, JAMA.

[44]  Sofia Dahlqvist,et al.  Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial , 2017, JAMA.

[45]  Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2019 , 2018 .

[46]  Aaron J. Kowalski,et al.  Standardizing Clinically Meaningful Outcome Measures Beyond HbA 1 c for Type 1 Diabetes : A Consensus Report of the American Association of Clinical Endocrinologists , 2017 .

[47]  T. Pieber,et al.  Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1). , 2017, Diabetes technology & therapeutics.

[48]  D. Owens,et al.  Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes , 2016, Diabetes Care.

[49]  Gerry Rayman,et al.  Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial , 2016, Diabetes Therapy.

[50]  Robert A. Vigersky,et al.  Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes , 2016, Diabetologia.

[51]  Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2016, Diabetes Care.

[52]  P. Geelhoed-Duijvestijn,et al.  Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial , 2016, The Lancet.

[53]  J. DeVries,et al.  Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. , 2016, The lancet. Diabetes & endocrinology.

[54]  Bruce W Bode,et al.  Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. , 2016, JAMA.

[55]  Martin Matoulek,et al.  Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study , 2016, Diabetes technology & therapeutics.

[56]  Roman Hovorka,et al.  Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. , 2016, The New England journal of medicine.

[57]  Irl B Hirsch,et al.  CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[58]  B. Olsen,et al.  Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose Management , 2016, Diabetes technology & therapeutics.

[59]  David Rodbard,et al.  Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. , 2016, Diabetes technology & therapeutics.

[60]  R. Beck,et al.  Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes , 2015, Diabetes Care.

[61]  D. Reda,et al.  Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. , 2015, The New England journal of medicine.

[62]  B. Charbonnel,et al.  Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. , 2015, Diabetes & metabolism.

[63]  A. Sinclair,et al.  Hypoglycemia in older people - a less well recognized risk factor for frailty. , 2015, Aging and disease.

[64]  A. Nicolucci,et al.  Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study , 2015, Acta Diabetologica.

[65]  Michael A. Wood,et al.  Sensor-augmented pump therapy for A1C reduction (STAR 3) study: Results from the 6-month continuation phase , 2013 .

[66]  Simon R. Heller,et al.  Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. , 2013, The Journal of clinical endocrinology and metabolism.

[67]  D. Klonoff,et al.  Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). , 2013, Diabetes technology & therapeutics.

[68]  M. Brod,et al.  Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians , 2012, Current medical research and opinion.

[69]  Yongming Qu,et al.  Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. , 2012, Diabetes technology & therapeutics.

[70]  David Rodbard,et al.  Hypo- and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution. , 2012, Diabetes technology & therapeutics.

[71]  B. Olsen,et al.  The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial , 2012, Diabetologia.

[72]  K. Blaine Lawlor,et al.  Smart Goals: How the Application of Smart Goals can Contribute to Achievement of Student Learning Outcomes , 2012 .

[73]  Michael A. Wood,et al.  Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study , 2011, Diabetes Care.

[74]  T. Christensen,et al.  The impact of non-severe hypoglycemic events on work productivity and diabetes management. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[75]  E. Ford,et al.  Iron‐deficiency anemia, non‐iron‐deficiency anemia and HbA1c among adults in the US * , 2011, Journal of diabetes.

[76]  Bruce A Buckingham,et al.  Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. , 2011, Diabetes technology & therapeutics.

[77]  Rodica Pop-Busui,et al.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial , 2010, The Lancet.

[78]  Dean Schillinger,et al.  Goal setting in diabetes self-management: taking the baby steps to success. , 2009, Patient education and counseling.

[79]  M. Hallschmid,et al.  Hypoglycemia Unawareness in Older Compared With Middle-Aged Patients With Type 2 Diabetes , 2009, Diabetes Care.

[80]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[81]  H. Murphy,et al.  Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial , 2008, BMJ : British Medical Journal.

[82]  Jeroan J. Allison,et al.  Reasons for Not Intensifying Medications: Differentiating “Clinical Inertia” from Appropriate Care , 2007, Journal of General Internal Medicine.

[83]  P. Damm,et al.  HbA1c levels are significantly lower in early and late pregnancy. , 2004, Diabetes care.

[84]  L. Bry,et al.  Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. , 2001, Clinical chemistry.

[85]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[86]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[87]  D G Schlundt,et al.  Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. , 1994, The Journal of clinical endocrinology and metabolism.

[88]  D. Rogers,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus , 1994 .

[89]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[90]  D Rodbard,et al.  Ambulatory Glucose Profile: Representation of Verified Self-Monitored Blood Glucose Data , 1987, Diabetes Care.